Clementia Pharmaceuticals Inc. An Ipsen Company

Research interest extends to musculoskeletal disease mechanisms, with emphasis on abnormal bone formation, skeletal tissue involvement, and the biological processes underlying progressive ossification.

• Bone formation
• Skeletal disorders
• Connective tissue disease

This area highlights therapeutic attention to disorders where bone develops inappropriately within soft tissues, creating significant functional impairment.

The sponsor’s clinical focus includes both paediatric and adult populations affected by a severe lifelong rare disease, with attention to age-specific clinical needs across the disease spectrum.

• Paediatric participants
• Adult participants
• Long-term disease management

Interest in these populations reflects the need for therapies suitable across developmental stages in a condition that can affect mobility, daily function, and disease progression over time.

Trial activity incorporates computed tomography-based assessment of new heterotopic ossification, indicating an interest in objective imaging measures for monitoring disease activity and treatment effect.

• Whole-body computed tomography
• Disease progression assessment
• Treatment response monitoring

This field supports evaluation of structural changes associated with progressive ossification in a rare musculoskeletal condition.

Current research interest includes an oral therapeutic approach for fibrodysplasia ossificans progressiva, with attention to both safety and efficacy in a rare disease setting.

• Oral treatment
• Safety evaluation
• Efficacy assessment

The therapeutic domain is centered on managing a disabling condition through medical intervention aimed at limiting abnormal bone growth.